1. Home
  2. TKO vs ROIV Comparison

TKO vs ROIV Comparison

Compare TKO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TKO Group Holdings Inc.

TKO

TKO Group Holdings Inc.

HOLD

Current Price

$201.96

Market Cap

14.5B

Sector

N/A

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.83

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKO
ROIV
Founded
1980
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5B
14.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TKO
ROIV
Price
$201.96
$21.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
8
Target Price
$223.25
$24.31
AVG Volume (30 Days)
1.1M
8.3M
Earning Date
02-25-2026
02-09-2026
Dividend Yield
1.54%
N/A
EPS Growth
N/A
N/A
EPS
1.85
N/A
Revenue
$2,545,175,000.00
$20,329,000.00
Revenue This Year
$69.99
N/A
Revenue Next Year
$29.73
$741.42
P/E Ratio
$109.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$133.07
$8.73
52 Week High
$218.11
$23.47

Technical Indicators

Market Signals
Indicator
TKO
ROIV
Relative Strength Index (RSI) 44.66 54.28
Support Level $201.60 $20.78
Resistance Level $218.11 $22.21
Average True Range (ATR) 3.60 0.66
MACD -2.16 -0.15
Stochastic Oscillator 8.56 40.50

Price Performance

Historical Comparison
TKO
ROIV

About TKO TKO Group Holdings Inc.

TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: